Brief: Talaris Therapeutics Initiates Phase 2 Clinical Trial Of FCR001 In Delayed Tolerance Induction
29/10/2021 12:51
Oct 29 (Reuters) - Talaris Therapeutics Inc TALS.O :
* TALARIS THERAPEUTICS ANNOUNCES INITIATION OF PHASE 2
CLINICAL
TRIAL OF FCR001 IN DELAYED TOLERANCE INDUCTION
Source text for Eikon: ID:nGNXQVqPj
Further company coverage: TALS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tourmaline Bio
See all newsBrief: Novartis Completes Acquisition Of Tourmaline Bio
Brief: Novartis Announces Expiration Of Tourmaline Bio Tender Offer
Novartis nears deal to acquire Avidity Biosciences for over $70 per share, Bloomberg News reports (updated)
Brief: Novartis Announces Commencement Of Tender Offer To Acquire Tourmaline Bio
U.S. STOCKS ON THE MOVE-Potbelly, Joby, Talen Energy